التفاصيل البيبلوغرافية
| العنوان: |
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada. |
| المؤلفون: |
Dai, Wei Fang, Beca, Jaclyn M., Croxford, Ruth, Isaranawatchai, Wanrudee, Menjak, Ines B., Petrella, Teresa M., Mittmann, Nicole, Earle, Craig C., Gavura, Scott, Hanna, Timothy P., Chan, Kelvin K.W. |
| المصدر: |
BMC Cancer; 4/15/2020, Vol. 20 Issue 1, p1-10, 10p, 1 Diagram, 3 Charts, 1 Graph |
| مصطلحات موضوعية: |
MELANOMA, COHORT analysis, THERAPEUTICS, CANCER treatment, REGRESSION analysis, THERAPEUTIC use of antineoplastic agents, DATABASES, RESEARCH, CLINICAL trials, RESEARCH methodology, ANTINEOPLASTIC agents, CASE-control method, METASTASIS, EVALUATION research, MEDICAL cooperation, TREATMENT effectiveness, COMPARATIVE studies, SURVIVAL analysis (Biometry), RESEARCH funding, LONGITUDINAL method |
| مصطلحات جغرافية: |
ONTARIO |
| مستخلص: |
Background: For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment's real-world effectiveness. We examined real-world population-based comparative effectiveness of second-line ipilimumab versus non-ipilimumab treatments (chemotherapy or targeted treatments).Methods: We used a cohort of melanoma patients receiving systemic treatment for advanced disease since April 2005 from Ontario, Canada. Patients were identified from provincial drug databases and the Ontario Cancer Registry who received second-line ipilimumab from 2012 to 2015 (treated) or second-line non-ipilimumab treatment prior to 2012 (historical controls). Historical controls were chosen, to permit the most direct comparison to pivotal trial findings. The cohort was linked to administrative databases to identify baseline characteristics and outcomes. Kaplan-Meier curves and multivariable Cox regression models were used to assess overall survival (OS). Observed potential confounders were adjusted for using inverse probability of treatment weighting (IPTW).Results: We identified 329 patients with metastatic melanoma (MM) who had received second-line treatments (189 treated; 140 controls). Patients receiving second-line ipilimumab were older (61.7 years vs 55.2 years) compared to historical controls. Median OS were 6.9 (95% CI: 5.4-8.3) and 4.95 (4.3-6.0) months for ipilimumab and controls, respectively. The crude 1-year, 2-year, and 3-year OS probabilities were 34.3% (27-41%), 20.6% (15-27%), and 15.2% (9.6-21%) for ipilimumab and 17.1% (11-23%), 7.1% (2.9-11%), and 4.7% (1.2-8.2%) for controls. Ipilimumab was associated with improved OS (IPTW HR = 0.62; 95% CI: 0.49-0.78; p < 0.0001).Conclusions: This real-world analysis suggests second-line ipilimumab is associated with an improvement in OS for MM patients in routine practice. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder